(Longeveron) Shares of Longeveron Inc. rose more than 37% on Thursday after its phase 1 study trials of Lomecel-B on patients with mild forms of Alzheimer disease showed success.
Longeveron said that the trials met its primary endpoint, with the trial drug showing tolerance in the patient group.
The company said that the study was published in The Journal of Alzheimer Association, with the results supporting further trials of Lomecel-B.
Geoff Green, CEO of Longeveron, said that the company was encouraged by the study publication in the high-impact journal, lauding Lomecel-B as a potential treatment for Alzheimer.
Mark Brody, a lead author of the manuscript, said the study was unique since it used cellular therapy, giving an opportunity to target multiple pathological features of Alzheimer.
LGVN: NASDAQ is up +37.46%
